CLINICAL TRIALS PROFILE FOR SUMATRIPTAN
✉ Email this page to a colleague
All Clinical Trials for sumatriptan
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00122278 ↗ | Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines | Completed | Montefiore Medical Center | Phase 3 | 2005-07-01 | Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines. Another problem with migraines is that although many times they get better after intravenous (IV) treatment in the emergency room (ER), about 1/3 of the time migraines recur the next day. The purpose of this research project is to see if adding a medication called dexamethasone to standard ER therapy will help patients get better quicker and stay pain-free more often than if they receive placebo. |
| NCT00184587 ↗ | Prophylactic Treatment of Episodic Cluster Headache | Completed | AstraZeneca | Phase 2 | 2005-03-01 | The purpose of this study is to determine whether candesartan cilexetil are effective prophylactic treatment of episodic Cluster headache |
| NCT00184587 ↗ | Prophylactic Treatment of Episodic Cluster Headache | Completed | Norwegian University of Science and Technology | Phase 2 | 2005-03-01 | The purpose of this study is to determine whether candesartan cilexetil are effective prophylactic treatment of episodic Cluster headache |
| NCT00240617 ↗ | Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks | Completed | GlaxoSmithKline | Phase 3 | 2005-10-01 | The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain. |
| NCT00240630 ↗ | Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks | Completed | GlaxoSmithKline | Phase 3 | 2005-10-01 | The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain. |
| NCT00274170 ↗ | Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache | Unknown status | C.R.Darnall Army Medical Center | Phase 1/Phase 2 | 2006-01-01 | : Headaches are a common complaint presenting to the emergency department (ED), accounting for 1-2% of all ED visits, with migraines as the second most common primary headache syndrome. Patients that ultimately present to the ED have failed outpatient therapy and exhibit severe and persistent symptoms. Treatment options have been traditionally with a parenteral opiod, generally Demerol. Unfortunately, patients with chronic painful conditions like migraines have been prone to dependency. In 1986, a nonopioid, compazine was noted serendipitously to relieve migraine headache pain. 1 Nonopioid regimens have evolved as standard therapy in the treatment of migrainne headache in the ED. Today, there are a number of nonopioid treatment options, but not without their own individual concerns. Ergotamine and dihydroergotamine are effective, but commonly cause nausea and vomiting. Sumatriptan is expensive has recurrence rate, is ineffective in about 20-30%, and is contra-indicated in patients with cardiac disease. Metoclopramide, a dopamine receptor antagonist, commonly used as an anti-emetic agent, has been widely studied for use with acute migraines. Its side effects include drowsiness and dystonic reactions. Compazine has been successfully used to treat migraine headaches for the past several decades, and has been accepted as standard treatment of headaches in the ED. 2 Its side effect profile includes extrapyramidal effects, dysphoria, drowsiness and akathisias. The ideal medication for treating headaches would have no addictive properties, few side effects, quick onset, be highly effective and have a low rate of recurrence. Somatostatin is known to have an inhibitory effect on a number of neuropetides, which have been implicated in migraine. Native somatostatin is an unstable compound and is broken down in minutes, but octreotide, a somatostatin analogue has a longer half life. Intravenous somatostatin has been shown to be as effective as ergotamine in the acute treatment of cluster headache. 3 The analgesic effect of octreotide with headaches associated with growth hormone secreting tumor has been established. 4 Five somatostatin receptors have been cloned with octreotide acting predominantely on sst2 and sst5. The distribution of sst2 within the central nervous system strongly suggests that this particular somatostatin receptor has a role in cranial nociception, being highly expressed in the trigeminal nucleus caudalis and periaqueductal grey. Kapicioglu et.al performed a double blind study comparing octreotide to placebo in treating migraine. They found there to be a significantly greater relief of pain with octreotide at 2 and 6 hours compared to placebo (76% vs 25%, p |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for sumatriptan
Condition Name
Clinical Trial Locations for sumatriptan
Trials by Country
Clinical Trial Progress for sumatriptan
Clinical Trial Phase
Clinical Trial Sponsors for sumatriptan
Sponsor Name
